A collaborative research alliance between New York University (NYU), Columbia University, and Takeda Pharmaceuticals is expected to propel advancements in drug development in gastroenterology and hepatology. Under the 5-year investigative partnership, Takeda Pharmaceuticals will provide seed funding for pilot and feasibility studies conducted at NYU and Columbia, with an overarching goal of innovating new treatment interventions for patients with gastrointestinal and liver disorders.
Takeda Pharmaceuticals is currently accepting proposals for studies from NYU and Columbia investigators, with the first set of trials under the alliance set to begin in the fall, according to a statement from NYU. The projects that demonstrate promising results in this initial round of evaluation will be eligible for additional funding to support further study.
At NYU and Columbia, the research collaboration will be led by Nigel Bunnett, PhD, and Timothy Wang, MD. Bunnett is professor and chair of the Department of Molecular Pathobiology at the NYU College of Dentistry. Wang is the Silberberg Professor of Medicine and GI Division Chief at Columbia University Vagelos College of Physicians & Surgeons.
“Through this unique partnership between academia and industry, our goal is to develop better drugs for common yet debilitating diseases of the liver and gastrointestinal system that are not well managed by existing therapies. It’s an exciting opportunity to cultivate projects in the lab and hopefully translate them into promising clinical treatments,” Bunnett said.
The research collaboration’s clinical areas of interest include gut inflammation, liver disease, motility disorders, translational and clinical research, drug delivery, and cell and gene therapy.
NYU, Columbia, and Takeda Form Research Alliance for Gastrointestinal and Liver Disorders. News release. New York University. November 23, 2020. Accessed December 2, 2020.